# Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.

> **NCT01262586** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **DRUG:** Vildagliptin
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT01262586
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01262586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01262586, "Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01262586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*